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Abstract: The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated 
to cost upwards of US$800 million for each drug to be successfully approved for clinical use. Much of this cost is driven 
by the late phase clinical trials and therefore the ability to terminate early those projects destined to fail is paramount to 
prevent unwanted costs and wasted effort. Although neglected diseases drug discovery is driven more by unmet medical 
need rather than financial considerations, the need to minimise wasted money and resources is even more vital in this un-
der-funded area. To ensure any drug discovery project is addressing the requirements of the patients and health care pro-
viders and delivering a benefit over existing therapies, the ideal attributes of a novel drug needs to be pre-defined by a set 
of criteria called a target product profile. Using a target product profile the drug discovery process, clinical study design, 
and compound characteristics can be defined all the way back through to the suitability or druggability of the intended 
biochemical target. Assessment and prioritisation of the most promising targets for entry into screening programmes is 
crucial for maximising chances of success. 
Keywords: Chemical validation, druggability, drug resistance, genetic validation, neglected diseases, molecular targets, target 
assessment, target product profile. 
DRUGS FOR NEGLECTED TROPICAL DISEASES 
  One sixth of the world’s population - approximately 1 
billion people - are infected with neglected tropical diseases 
(NTDs) including the vector-borne parasitic diseases, Afri-
can sleeping sickness, Chagas disease, leishmaniasis, filaria-
sis, onchocerciasis and schistosomiasis [1]. Although, the 
existing drugs used to treat many NTDs have serious limita-
tions, only 1% of all new drugs to reach the market in the 
past 25 years were for neglected diseases [2]. Issues with 
current therapies include: cost; difficulties in administration; 
poor safety profile; and lack of efficacy e.g. due to drug re-
sistance [3,4]. In total, NTDs account for 5% of the global 
disease burden; yet, it is estimated only about 0.1% of global 
research budgets are spent on drug discovery for these dis-
eases. This lack of resource is compounded by the high attri-
tion rates for drug discovery, as only 1 in 5 projects survives 
through preclinical development and less than 1 in 10 enter-
ing clinical development are finally registered for clinical 
use [5]. Most projects fail either through issues with the un-
derpinning biology. For example, selected targets are often 
subsequently revealed as not essential for parasite growth or 
survival and a multitude of potential pitfalls are encountered 
along the drug discovery pathway, including: failure to iden-
tify suitable drug-like lead compounds for optimization; lack 
of efficacy, often in clinical trials; toxicity and drug metabo-
lism and pharmacokinetic (DMPK) issues. 
  Despite substantial research into the biology of these 
parasites and the sequencing of their genomes, discovery of 
candidate drugs is hampered by the lack of well validated 
druggable targets as many essential genes are not druggable. 
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In addition the translation of genetic validation of targets 
into candidate compounds with potent anti-parasitic effects 
suffers from high rates of attrition. Therefore, there is a need 
for well validated and characterised targets, which can de-
liver drug candidates capable of addressing the Target Prod-
uct Profiles (TPP), i.e. the desired properties and efficacy of 
the drug, for these diseases. In consequence, the purpose of 
this review is to illustrate how molecular targets are assessed 
for entry into a drug discovery pipeline, taking into account 
of needs of the patients as defined by the TPP. The authors 
hope this discussion will encourage researchers to generate 
the required data for target assessment as a matter of course 
during their research, thereby producing sufficient potential 
anti-parasitic drug targets to support future drug discovery 
efforts. 
  This review will focus on the molecular target approach 
to drug discovery and how the use of TPPs for individual 
diseases can help to accelerate the drug discovery process 
and help to reduce the high attrition rates seen during drug 
discovery and development. In addition, this approach 
should also be used to assess and develop compound series 
identified by in vitro screening against whole parasites, a 
valuable alternative strategy for anti-parasitic drug discovery 
[6
_9]. 
TARGET PRODUCT PROFILES 
  For drug projects to succeed in delivering the right medi-
cine for the right patient there must be from the outset a clear 
understanding of the critical features of the final therapeutic 
product for clinical use. These features are defined in the 
Target Product Profile (TPP), which is a listing of the essen-
tial attributes required for a specific drug to be a clinically 
successful product and to be of substantial benefit over exist-
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  The TPP is an important strategic planning and decision-
making tool [10,11] that is used to define: the target patient 
population; acceptable levels of efficacy; acceptable levels of 
safety; the dosing route; the dosing schedule; the properties 
of the formulated drug; and acceptable levels of cost of the 
formulated drug. To compile a TPP it is essential that there is 
a good knowledge of the patient’s needs, so it is important to 
include information provided by health care workers and 
physicians, health regulators and policy makers, especially 
from disease endemic countries. In addition, the TPP needs 
to take into account the existing therapies and define those 
attributes required for the new therapy to present a signifi-
cant advance over the current clinically used drugs. The TPP 
has to be periodically reassessed with regard to meeting es-
sential, preferred or minimal acceptable criteria, as the unmet 
clinical need changes with the development of competing 
drug candidates and emerging data from clinical trials. 
  By way of example, two contrasting parasitic diseases 
TPPs are shown in Table 1. This profile should be used as 
the basis for assessing project feasibility, monitoring pro-
gress and guiding drug discovery and development activities 
throughout the critical path for the entire research and devel-
opment process. In this role the TPP provides the informa-
tion necessary for: selection of targets; selection of screening 
hits and chemical start points for optimisation; the optimisa-
tion of drug candidates; objectivity for the project decision 
making process; better design of clinical trials; and open and 
constructive communication with the regulatory agencies. 
  The TPP can be used during the earlier phase of the drug 
discovery process to define the attributes required for drug 
development candidates or compound series to pass from 
one phase of the drug discovery process to the next. In fact, 
consideration of TPPs can be taken right back to the ap-
praisal and selection of targets and hits from screening cam-
paigns. Clearly defining a TPP and using it to define criteria 
for progression from one phase of the drug discovery process 
to another helps to deliver benefits from better decision mak-
ing, faster development times and higher approval success 
rates to bring a drug to market. Most importantly this ap-
proach helps to define targets and compound series which 
will never achieve the TPP and therefore never benefit pa-
tients, facilitating the rapid closure of such projects and al-
lowing the realignment of valuable resource into potentially 
more productive areas. 
MOLECULAR TARGET ASSESSMENT 
  In order to initiate a drug discovery programme, a pool of 
putative targets will require assessment to identify those 
which offer the best chance of delivering drug candidates to 
address the unmet medical need. The process thereafter is 
beset with potential pitfalls and high attrition seen in all drug 
discovery endeavours; however the chances of ultimate suc-
cess can be increased by intelligence-based assessment and 
selection of these targets. This assessment needs to remain in 
the context of the TPP to ensure the unmet medical need is 
truly being addressed. This target assessment and prioritisa-
tion process is well established in the drug discovery indus-
try, so this article will illustrate how this paradigm can be 
appropriately applied to assess targets to establish a parasitic 
disease discovery pipeline. The criteria of key importance
Table 1.    Parasitic Disease Target Product Profiles for Human  
                  African Trypanosomiasis and Malaria
a
General desired features for a drug include: 
o Therapeutic area 
o Spectrum of activity (e.g. active against all species including 
drug resistant isolates) 
o Target population (e.g. pregnant women and children) 
o Dose, frequency and route of administration (e.g. once a day, 
oral route) 
o Safety and efficacy (better than existing treatments) 
o Toxicity (minimal side effects, better than existing treat-
ments) 
o Potential for use in drug combinations (minimise emergence 
of resistance) 
o Few contraindications (e.g. minimal drug-drug interactions; 
suitable for use in HIV/AIDS or TB co-infections) 
o Low potential of developing parasite resistance 
o Stability under tropical conditions (i.e. > 2 years shelf life at 
40 °C  and 75% relative humidity) 
o Cost of goods (i.e. equivalent to or cheaper than existing 
treatments) 
A TPP for uncomplicated falciparum malaria includes: 
o Oral (ideally once per day for not more than three days) 
o Low cost of goods (~US$1 per full course of treatment) 
o Effective against drug-resistant parasites (e.g. those that have 
developed resistance to chloroquine or Fansidar) 
o Fast acting and curative within three days 
o Potential for combination with other agents 
o Paediatric formulation should be available 
o Stable under tropical conditions 
A TPP for human African trypanosomiasis (HAT) includes:   
o Active against T.b.gambiense and T.b.rhodesiense
o Active against melarsoprol refractory strains  
o Efficacy against early and late-stage disease desirable 
o Formulation (oral against early stage desirable; parenteral 
against late stage acceptable) 
o Curative in 14 days (late stage) or less (early stage) 
o Cost less than current treatment for early stage disease ($100-
140) 
o Safe in pregnancy 
o Stable under tropical conditions 
aAdditional TPPs for neglected diseases such as schistosomiasis are available else-
where [3]. Further details of the various TPPs for other malaria indications are avail-
able from Medicines for Malaria Venture (MMV) website (http://www.mmv.org/). 
Additional desirable and acceptable criteria for visceral leishmaniasis and Chagas’ 
disease are available from Drugs for Neglected Diseases initiative 
(http://www.dndi.org/) 
used to assess targets are described in Table 2. A scoring 
system using the globally familiar colours of traffic lights is 
applied for each criterion. Scoring each target with the traffic 
light system affords an initial overall view of the pipeline 
under consideration, allowing a ranking of the portfolio, 
identifying the most mature targets and highlighting any key 
areas of weakness. In the suggested model, for most cases, a 
red assignment is not an absolute “stop”, but represents the 
current status of the target and highlights where further stud-
ies and/or reagents are required in order to advance a target 
towards readiness for entry into the drug discovery pipeline.Target Validation: Linking Target and Chemical Properties  Current Topics in Medicinal Chemistry, 2011, Vol. 11, No. 10    1277
Table 2.  Traffic Light Definitions for Target Assessment Used in the Drug Discovery Unit at the University of Dundee. 
Criterion Red  Amber  Green 
Target validation 
No or weak evidence that the target is 
essential for growth or survival 
Either genetic or chemical evidence that 
target is essential for growth or survival 
a
Genetic and chemical evidence that tar-
get is essential for growth or survival
 a
Druggability 
No drug-like inhibitors are known and 
active site of target is not druggable 
Drug-like inhibitors are known or active 
site potentially druggable 
Drug-like inhibitors are known and drug-
gable active site (i.e. clinical precedent 
within the target family) 
Assay feasibility 
No  in vitro assay developed and / or 
significant problems with reagents (cost 
or supply) 
In vitro assay exists, development into 
plate format feasible, but not achieved 
Assay ready in plate format and protein 
supply assured within appropriate time-
lines 
Toxicity 
Human homologue present and little or 
no structural or chemical evidence that 
selective inhibition is possible 
Human homologue present, but some 
structural or chemical evidence that 
selective inhibition is possible 
No human homologue present or human 
homologue known to be non-essential 
Resistance potential 
Target has multiple gene copies or iso-
forms within same species and is subject 
to escape from inhibition 
b
Target has isoforms within same species 
or may be subject to escape from inhibi-
tion 
b
Target has no known isoforms within 





No structure of target or closely related 
homologue 
Structure without ligand available and / 
or poor resolution (> 2.3 Å) or opportu-
nity to build a good homology model 
Ligand bound structure of target (or 
ligand in closely related homologue) 
available at high resolution (< 2.3 Å) 
aSee Table 3 for the relative merits of genetic and chemical validation. 
bPossible resistance mechanisms include: accumulation of substrate that could reverse inhibition; or target can be deleted, readily modified by point mutation, readily amplified or by-
passed. 
It is important to note that some targets are more likely to fit 
certain TPPs than others. For example, targets that are pre-
dicted to be rapidly cidal following inhibition by small 
molecules are preferable to those that are slowly cidal or 
simply cytostatic, particularly if a fast response to drug 
treatment is specified by the TPP. This also has implications 
from a pharmacological perspective, since compounds that 
are cytostatic require prolonged and sustained exposure lev-
els above the minimal inhibitory concentration to be cura-
tive. For example, the prolonged therapeutic schedule re-
quired for treatment of human African trypanosomiasis with 
the cytostatic drug, eflornithine [12] suggests that ornithine 
decarboxylase is not an ideal target for further drug discov-
ery. There are also immunological implications, since cy-
tostatic drugs require an effective host immune response in 
order to obtain cures. For example, the cidal drug, liposomal 
amphotericin B is the current treatment of choice for visceral 
leishmaniasis in cases co-infected with HIV [13]. 
TARGET VALIDATION: TWO COMPLEMENTARY 
APPROACHES 
  With the wisdom of hindsight, failure of target-based 
drug discovery campaigns can often be attributed to inade-
quate scientific knowledge about the functional roles of a 
molecular target under physiological conditions inside and 
outside a cell. The two main complementary approaches to 
target validation can be categorised as “chemical” and “ge-
netic”, where small molecule inhibitors or genetic methods 
can be used to modulate the functional activity of a target. 
Broadly speaking, the former provides chemical evidence for 
druggability of the target and favourable selective toxicity 
against the pathogen versus the host (cell, tissue or whole 
animal), while the latter provides genetic evidence of essen-
tiality of function within the pathogen. Tools are available to 
achieve either target knockdown (e.g. reversible inhibitors or 
RNA interference) or target knockout (e.g. irreversible in-
hibitors or gene deletion). As summarised in Table 3 and 
discussed below, neither method on its own is sufficiently 
robust to provide absolute proof of essentiality and, when-
ever feasible, complementary and confirmatory evidence 
should be sought using both approaches. 
  Chemical validation involves the use of drugs or experi-
mental compounds to provide evidence that specific inhibi-
tion of a target results in inhibition of growth or death of the 
parasite. Most parasites display complex life cycles between 
their vertebrate and invertebrate (vector) hosts and can 
modulate their metabolic activities in response to changes in 
the external environment (e.g. pH, temperature, nutrient 
availability). Thus, the strength of chemical validation in-
creases in the following order: (i) in vitro activity against 
vector stages; (ii) in vitro activity against host stages; (iii) in
vivo activity in animal models; and, best of all, (iv) therapeu-
tic activity in patients. The major advantage of the chemical 
approach is that it addresses several key druggability issues: 
cell permeability and selective toxicity in whole cell assays 
in vitro; suitable drug metabolism and pharmacokinetic 
(DMPK) properties in vitro and in vivo; and acceptable 
safety and efficacy profile in appropriate animal models. 
  Chemical approaches also have the distinct advantage in 
being able to identify non-protein targets that could not be 
predicted from analysis of the genome. Classical examples 
are: detoxification of haem into haemozoin in malaria para-
sites, the target for 4-aminoquinolines such as chloroquine 
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Table 3   Strengths and Weaknesses of Different Target Validation Methods (Modified From [11]) 
Method Strengths  Weaknesses 
Chemical validation 
￿ Addresses the key druggability issues of cell permeability 
(in vitro whole cell assays); selective toxicity and drug 
metabolism (in vivo animal models); safety and efficacy 
(clinical) 
￿ Identifies non-protein targets 
￿ Identifies pro-drugs and compounds acting by lethal syn-
thesis 
￿ Highly specific inhibitors frequently not available 
￿ Lack of specificity for target resulting in poor structure-
activity-relationships (SAR) 
￿ Variable cellular pharmacokinetics can cause poor SAR 
￿ Correlation between target inhibition and predicted mo-
lecular or biochemical phenotype sometimes difficult to 
demonstrate in vitro or in vivo 
All genetic valida-
tion 
￿ Many complete genomes available 
￿ Suitable for genes of unknown or uncertain function 
￿ Cannot identify non-gene targets (e.g. haemozoin) 
￿ Does not address key druggability issues 
￿ Does not identify drugs acting via lethal synthesis 
￿ Does not distinguish between structural and catalytic re-
quirement 
Knockout methods 
￿ Definitive, “clean” phenotype 
￿ Few or no off-target effects 
￿ Laborious (usually requires multiple transfections in dip-
loid organisms) 
￿ Null mutants for essential genes require genetic or nutri-
tional rescue 
￿ Multicopy genes can be problematic 
￿ Compensatory (suppressor) mutations can occur 
RNA interference 
(RNAi) 
￿ Rapid and easy to perform 
￿ Suitable for multicopy gene families 
￿ Not possible in many parasite species 
￿ No phenotype due to insufficient silencing 
￿ Off-target effects due to unintentional silencing 
￿ “Escape” mutants with essential genes 
leishmania, the target for amphotericin B [16,17]. Chemical 
methods can also uncover compounds (pro-drugs) that un-
dergo bio-activation to highly toxic compounds (lethal syn-
thesis). For example, trypanosomes are highly susceptible to 
nitro-heterocyclic compounds such as nifurtimox through 
metabolic activation by a number of mechanisms [18
_21]. 
Likewise, leishmania, but not humans, can convert allopuri-
nol into aminopyrazolopyrimidine ribonucleotides with sub-
sequent incorporation into RNA [22]. Finally, some drugs 
are thought to act via “selective distribution” [23], where 
compounds are selectively concentrated by parasite trans-
porters. The melaminophenyl class of arsenical drugs used to 
treat African sleeping sickness is a classic example of this 
mechanism [24
_26]. None of these targets could be reliably 
predicted with the currently available tools to analyse para-
site genomes. 
  However, there are weaknesses to the chemical valida-
tion approach. Highly specific inhibitors are usually not 
available at the outset of a discovery campaign. Conse-
quently, structure-activity-relationships between target (IC50)
and whole cell (EC50) inhibitory potency may be poor, due to 
lack of specificity or variable cellular pharmacokinetics. This 
is especially true for less specific generic inhibitors against 
target classes such as protein kinases and proteases. Demon-
stration that compounds are acting “on-target” can also be 
technically difficult. Moreover, identification of the target 
(or targets) for a small molecule inhibitor identified through 
a whole cell phenotypic screen can present significant chal-
lenges. 
  Genetic approaches to target validation can be broadly 
classified as target (gene) knockout and target (RNA) 
knockdown methodologies. If structural and mechanistic 
knowledge of the target is known, then a dominant-negative 
approach to target suppression can be employed in some 
situations [27]. A novel strategy, which may be more gener-
ally applicable, involves expression of a mutated FK506-
binding protein fused to the N-terminus of the target. The 
stability of the fusion protein is dependent on binding of the 
ligand FK506 – removal of the ligand destabilises the FKBP 
domain resulting in protein degradation. To date the method 
has been successfully used in P. falciparum [28,29], T.gondii
[30] and L.major [31]. However, it should be born in mind that 
addition of FKBP could interfere with correct assembly of pro-
tein complexes, enzyme function or subcellular targeting. 
  The particular methodology employed for genetic valida-
tion depends on the molecular toolbox available for any 
given organism (see reviews [32,33]). The available tools are 
limited by factors such as the availability of inducible or 
non-inducible expression vectors; the range of drug-
selectable markers; and the genetic and physiological proper-
ties of the organism under study (e.g. gene copy number, 
ploidy; ease of culture in defined media; susceptibility to 
drug selection; ease of transfection; sexual recombination). 
Genetic manipulation of Leishmania and Trypanosoma
[33,34] is generally easier than that of Plasmodium [35], 
although genetic manipulation of the related apicomplexan 
parasite,  Toxoplasma gondii [36], can provide clues about 
probable outcomes in malaria. 
  The genetic approach of targeted gene disruption or gene 
replacement (gene knockout) is generally regarded as the 
most definitive method for target validation [37,38]. This 
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carrying a selectable marker (typically a gene conferring 
resistance to a drug) flanked by 5'- and 3'-flanking sequences 
of the target gene of interest. Following transfection, ho-
mologous recombination occurs in some of the population 
such that the target gene is replaced with a drug resistance 
gene in the chromosome. Cells lacking this replacement are 
eliminated by selection with a toxic agent, such as G418, 
hygromycin or phleomycin. For cells that are diploid or con-
tain multiple copies of the target gene dispersed in the ge-
nome, multiple rounds of transfection with additional select-
able markers are required to remove all gene copies. Alterna-
tively, stepwise selection with increasing concentrations of 
drug can sometimes lead to replacement of the second allelic 
copy of the target by the gene for the selectable marker, a 
process known as “loss of heterozygosity” [39,40]. 
  If null mutants can be generated by either of the above 
methods, then the target is not essential for survival for that 
particular life cycle stage, under those specific in vitro cul-
ture conditions. Clearly, if the biochemical phenotype can be 
predicted, then null mutants can be obtained by nutritional 
rescue with an appropriate supplement in the medium. For 
example, ornithine decarboxylase deficiency can be rescued 
by putrescine [41,42] or thymidylate synthase deficiency 
rescued by thymidine [43]. Since these culture conditions are 
not identical to the physiological milieu in vivo, where feasi-
ble, it is important to demonstrate that transgenic parasites in 
the correct life-cycle stage are not infectious in an appropri-
ate animal model [44
_46]. Unfortunately, this is rarely done. 
  For essential genes, multiple rounds of transfection either 
fail to generate any cell-lines that are resistant to the drugs 
used for selection or evade gene replacement by various 
mechanisms. Escape mechanisms include: insertion of the 
selectable marker into another part of the genome; increase 
in chromosome number (e.g. aneuploidy or tetraploidy) [47] 
or compensatory genetic mutations [48]. These “escape mu-
tants” can be regarded as suggestive of essentiality [47], but 
should be backed up with additional studies such as nutri-
tional rescue (see above) or genetic rescue experiments. In 
the latter case, this is achieved by insertion of another copy 
of the target (sometimes from a related species) either on an 
episomal vector or at another chromosomal locus [33
_36]. 
Although this method is widely applicable, unfortunately, 
this reveals no information as to precisely what level of en-
zyme activity is compatible with growth or survival and con-
sequently what level of inhibition has to be achieved by drug 
treatment. Where possible, inducible or repressible gene-
expression system(s), such as the tetracycline-inducible sys-
tems for trypanosomes should be used instead [49
_51]. 
  At the RNA level, target levels can be knocked down by 
RNA interference (RNAi) by expression of double-stranded 
RNA (dsRNA) [52]. This method is only applicable at pre-
sent for African trypanosomes [53] and possibly one species 
of leishmania parasite [53,54]. Inducible expression of 
dsRNA is preferable to constitutive expression, since trans-
genic organisms lacking an essential biochemical component 
generally cannot be selected – only “escape mutants” can be 
recovered making interpretation difficult. However, even 
with inducible systems, insufficient expression of dsRNA 
may fail to knock down target expression to levels required 
to reveal a phenotype. Thus a “negative” result in the ab-
sence of careful phenotypic characterization of target expres-
sion has little value. A “positive” result, where growth inhi-
bition correlates with decreased target production, can be 
quite helpful. However, even positive results can be prob-
lematic, if RNAi causes “off-target” effects. To circumvent 
this concern, it is sometimes possible to rescue the RNA 
phenotype by expression of a gene from another species that 
differs sufficiently at the nucleotide level to be refractory to 
RNAi, as was recently demonstrated using L. major sper-
midine synthase expressed in T. brucei, [55]. 
  As can be seen from the above discussion target knock-
out or knockdown is not without its limitations, emphasising 
the need for both chemical and genetic evidence to increase 
confidence that a putative target is both essential and drug-
gable. When specific inhibitors are available then it is possi-
ble to employ a hybrid approach. Here, modulation of target 
levels through under- or over-expression can be used in con-
junction with specific inhibitors to demonstrate on-target 
activity in intact cells through a corresponding shift in cell 
potency [44,56]. 
DRUGGABILITY AND DRUG LIKENESS 
  In the 1990’s a high percentage of compounds entering 
clinical development failed for poor pharmacokinetic (PK) 
properties. Consequently, the pharmaceutical industry 
adapted to address PK a lot earlier in the drug discovery 
process. The result has been dramatic, and by the turn of the 
century, attrition had been significantly reduced in the clinic 
due to adverse PK and poor bioavailability [57]. 
  In the search for understanding compound attrition due to 
poor PK, the “rule of 5”, also known as “Lipinski rules” 
[58], was introduced, and compounds that adhere to these 
rules were coined as “druggable” or “drug-like”. More re-
cently, the terms “druggable protein” and “druggable ge-
nome” have been used in the context of protein targets that 
can bind drug-like compounds [59] such that “druggability” 
is the likelihood of being able to modulate a protein target 
with a small drug-like compound. 
  Traditionally, the selection of targets for drug discovery 
rarely included an assessment of the likelihood of discover-
ing drug-like ligands [5]. This omission has contributed to 
the failure of many screening campaigns [60], as the binding 
sites of many targets are too large or too small, too polar or 
lack sufficiently deep binding pockets to potently bind drug-
like compounds. It is therefore crucial that any new drug 
discovery project target is druggable and consequently of 
higher probability of successfully progressing from hit to 
lead. 
  There has been much debate about what proportion of the 
human genome is druggable, currently estimated at 8-12% of 
all genes [59]. This statistic is currently unknown for patho-
gens, but is likely to be similar. However, this raises the im-
portance of being able to predict how druggable a novel 
pathogen target is in early drug discovery. There are a num-
ber of well documented approaches available to identify po-
tential druggable targets. A target’s druggability is usually 
estimated by classifying it with known gene families that 
have been successfully targeted with small drug-like com-
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binds drug-like compounds, other members will do so, as 
binding-site architecture is generally conserved between 
gene family members. More recently however, newer ap-
proaches to predicting druggability have been reported. No-
tably, Hajduk and co-workers [61], using nuclear magnetic 
resonance data on the interactions of 10,000 lead-like or 
fragment-like compounds with protein surfaces, developed 
druggability indices that can be used for the computational 
assessment of proteins with known structure. Likewise, 
Cheng and co-workers [62] have devised a mathematical 
model that uses structural information about a target's bind-
ing site to estimate druggability. These new paradigms of 
assessing the suitability of targets for entering hit discovery 
represent potentially exciting ways of reducing the current 
high rates of attrition. 
  However, as stated by Keller  [63], it has never been 
challenging to find inhibitors of proteins with questionable 
druggability. The real druggability challenge arrives when 
these leads have to be turned into orally bioavailable drug 
candidates that have suitable properties to successfully ad-
vance through clinical development. 
  The value of including physicochemical property guide-
lines [58,64] in the selection of leads was an important step 
forward in starting with a foundation of leads that are free 
from major liabilities that would later impede the accom-
plishment of a viable clinical candidate. 
  During lead optimisation substructures are added onto the 
lead to enhance target affinity and selectivity. Non-polar 
groups are added to enhance binding to lipophilic pockets 
and other groups added to increase hydrogen bonding with 
the binding site. This adds lipophilicity, molecular weight 
and hydrogen bonding to the lead and can be highly detri-
mental to the pharmacokinetic properties of the compound. 
Consequently drug candidates that are rule-of-5 compliant 
would be easier to find if libraries are lead-like, only con-
taining compounds with lower molecular weight, lower lipo-
philicity, and fewer hydrogen bonds so that once optimised, 
the candidate compound is still drug-like. 
  There are limitations to the rule of 5 as this only applies 
to compounds that are delivered by the oral route. If the TPP 
allows an alternative route of administration other than oral, 
then there may be room for flexibility in physicochemical 
properties and appropriate adjustments to the initial drug-like 
properties of a lead factored in. Injectable compounds can be 
significantly heavier, more polar and more flexible than oral 
compounds [65]. Furthermore, an injectable compound 
should have higher solubility than an oral compound. In-
haled compounds can also be heavier, more polar and have a 
higher polar surface area than orally administered com-
pounds [66]. In contrast the properties of topical compounds 
are similar to an oral compound [65]. 
  Additionally, the site of action of the potential drug needs 
to be considered. If the compound is to be delivered by the 
oral route, but must also cross the blood-brain barrier to ex-
ert its effect, as for stage 2 HAT, additional considerations 
need to be made in further restricting the physicochemical 
properties of the initial lead-like compounds. For compounds 
required to cross the blood-brain barrier, restricted Lipinski 
rules have been adopted for selecting initial lead templates. 
Notably, a significantly lower polar surface area to that re-
quired for oral bioavailability [67] is required. 
  The properties of the final compound also have to com-
ply with TPP requirements such as drug stability and cost of 
goods. For such diseases, both the candidate compound and 
the formulated form of the drug need to be stable for ex-
tended periods, 2-3 years, under tropical conditions, as it is 
undesirable and unpractical in many situations to have tem-
perature controlled storage systems. Therefore the compound 
classes developed need to be devoid of functionality that is 
inherently unstable, such as those commonly found in irre-
versible inhibitors. In addition the formulations used to de-
liver the drugs need to be simple and not to require special 
storage conditions. 
  For compounds to comply with strict restrictions on the 
cost of treatment, the candidate compounds in turn have to 
be to cheap to make using low cost intermediates and high 
yielding, straightforward chemistry involving a limited num-
ber of synthetic steps. Therefore, early judgements can be 
made when assessing the targets and hits from screens, 
whether they will deliver compounds of low complexity and 
cost. 
  Integrating the concepts of drug likeness and druggability 
for both target selection and lead selection into the drug dis-
covery process should ultimately reduce the current high 
rates of attrition in the hit to lead and lead optimisation proc-
ess. 
RESISTANCE POTENTIAL 
  Development of resistance during the use of antimicrobi-
als is almost inevitable and therefore, strategies must be 
adopted in clinical use of antimicrobials to deal with this. 
One of the most widely used strategies is combination ther-
apy, using compounds targeting different pathways or with 
different patterns of mutations preventing cross-resistance if 
acting on the same target [13,68
_70]. Despite this, many anti-
infective programmes take place against a background of the 
need to replace existing drugs due to the emergence of resis-
tance. This need will be reflected in the TPP. Thus, the tar-
gets investigated need to be assessed for their ability to avoid 
cross resistance with the current therapies. Indeed, an advan-
tage would be gained if the parasite biology suggested the 
target under consideration could be synergistic with the cur-
rently used drugs. 
  When assessing potential new targets, the underlying 
biology would suggest that in some cases there may be facile 
routes of resistance, which will rapidly reduce the clinical 
effectiveness of any particular drug. Identifying these 
mechanisms during target validation is important, as it will 
reflect on the validity of a target and maybe preclude the 
development of the target into drug discovery. 
  Resistance can arise from a number of different sources: 
point mutation of the target enzyme; over-expression of the 
target enzyme; efflux of the drug from parasites via trans-
porters; reduced drug uptake through transporters; induced 
metabolism of the drug; and use of by-pass pathways. It is 
also possible that a pathogen can adapt to living in the pres-
ence of a chemotherapeutic agent, for example through in-Target Validation: Linking Target and Chemical Properties  Current Topics in Medicinal Chemistry, 2011, Vol. 11, No. 10    1281
creased uptake of metabolites downstream of the point of 
inhibition in a pathway. 
  Identification of potential mechanisms of resistance can 
be difficult to achieve. However, analysis of the relevant 
genome can help to identify some mechanisms, such as po-
tential by-pass mechanisms and orthologous proteins. 
  Therefore, when selecting a drug target, potential mecha-
nisms of resistance need to be considered. It has to be noted 
though, that development of resistance in a laboratory setting 
does not necessarily mirror what will happen in a clinical 
setting. 
TOXICITY PROFILES 
  One of the key aspects covered within a TPP is the ac-
ceptable toxicity profile of the prospective drug candidate. 
Therefore, when selecting a target for a drug discovery pro-
gramme, an important consideration is the potential of 
modulation of the target or the compounds required to modu-
late the target to give rise to toxicity. Toxicity can arise via a 
number of sources, such as inherent toxicity due to modula-
tion of a host target, modulation of host targets that are close 
homologues of the parasite target under consideration, 
modulation of unrelated human enzymes or receptors, and 
toxicity due to the structure of a drug or the metabolite of a 
drug. 
  The level of acceptable toxicity for any treatment will 
depend on a number of factors including: the severity of the 
disease; the target patient population; the existence of other 
treatments; the clinical setting; and the length of proposed 
treatment. Thus for a life-threatening disease, such as certain 
cancers for which there is no other treatment, then a higher 
level of toxicity could be acceptable, than for a non life-
threatening disease such as pain management, for which 
other treatments exist. 
  Although many neglected diseases are life threatening, 
the target population will be made up of a significant propor-
tion of women of childbearing age and children. In addition, 
the vast majority of patients have very limited access to so-
phisticated medical support, therefore complex monitoring 
of drug levels or toxicity indicators is impractical; conse-
quently, safety profiles need to reflect these special needs. 
  In terms of assessing toxicity, the inherent toxicity of a 
molecular target can be minimised in the case of anti-
microbial chemotherapy by targeting parasite specific en-
zymes and processes which have no analogues in human. 
However, many of these targets have no history of drug dis-
covery and some are of dubious druggability. Therefore, 
many of the most promising targets have human homologues 
requiring in most instances for the compounds to be highly 
selective for the microbial target over a corresponding hu-
man enzyme. For many targets there will be sufficient differ-
ences to derive selectivity. Conversely, where there is very 
high structural similarity between some pathogen targets and 
their human homologues, inhibition of such a target is likely 
to give rise to toxic effects. In consequence this particular 
molecular target is very unlikely to satisfy a TPP, as it will 
be very difficult to obtain selective compounds, unless the 
differences of the function in human and parasite cells al-
lowed selectivity at the level of the biology of the system. 
  For example, a number of anti-proliferative kinase inhibi-
tors have been developed as anti-cancer agents, which could 
have interesting anti-proliferative activity against parasite 
kinases. However, by their very nature these compounds are 
likely to be teratogenic or foetotoxic precluding their use for 
women, as it would be difficult to test for pregnancy in a 
neglected diseases clinical setting. Therefore, parasite kinase 
inhibitors will need to be either designed and/or profiled to 
ensure selectivity over anti-proliferative human kinases. The 
development toxicology package would need to be designed 
to include reproductive toxicity studies at an early stage to 
ensure the compounds are not teratogenic or foetotoxic. 
  At the target assessment stage the type of compounds 
required to inhibit the proposed target needs to be considered 
for their toxicity potential. Prediction of toxicity using in
silico methodology is still in its relative infancy. Therefore 
during the drug discovery process, potential liabilities should 
be identified as early as possible through appropriate assays, 
allowing go/no-go decisions to be made on particular chemi-
cal series and targets. During early stage discovery, removal 
of compounds with functional groups associated with toxic-
ity (e.g. Michael acceptors) and testing of key compounds 
for liabilities, such as potentially fatal cardiotoxicity due to 
inhibition of the hERG potassium channel, should help to 
reduce compound-associated toxicity. Irreversible inhibitors 
are often proposed as modulators of poorly druggable tar-
gets, such as certain proteases. However, the intrinsic reac-
tivity of these compounds make them more likely to be toxic 
either through direct interaction with host enzymes or 
through reaction with protein residues, which can induce 
immunogenicity. Again these compounds could be toxic to 
rapidly dividing cells including those of a foetus. If com-
pounds of this type are developed the toxicity programme 
would need to reflect the increased chance of such toxicity. 
  The development programme of drug candidates, includ-
ing the toxicology studies, needs to take into account the 
differences seen in drug metabolism and transport across 
ethnic groups, known as pharmacogenetics [71]. For exam-
ple, there is variability in the expression levels and isoform 
expression of cytochrome P450s across different ethnic 
populations. This variability can cause either a decrease or 
increase in exposure to an experimental compound resulting 
in a loss of activity, or a potential increase in toxicity respec-
tively. In addition, differing expression of P450 isoforms 
could change the metabolic routes of compounds causing the 
production of metabolites not accounted for in toxicity stud-
ies or cause unexpected drug-drug interactions in cases 
where patients are likely to be on several medicines at the 
same time, due to difference in P450 inhibition profiles. 
Therefore, it is important the pre-clinical and clinical studies 
reflect the ethnicity of the intended patient population. 
CONCLUSION 
  The landscape of neglected diseases drug discovery is 
beginning to change dramatically with the establishment of 
credible and productive PPP and the rekindling of interest 
from the Pharma sector. These changes in turn are encourag-
ing the development of new collaborations between aca-
demic groups, PPPs and Pharma partners. 1282    Current Topics in Medicinal Chemistry, 2011, Vol. 11, No. 10 Wyatt et al.  
  Despite these encouraging developments, there hangs the 
spectre of the high attrition rates experienced by all sectors 
involved in drug discovery. Therefore, in this still under re-
sourced area of drug discovery, there needs to great clarity 
around the aims and goals of the mission and clear decision 
making associated with each project. To this end Therapeutic 
Product Profiles are coming to the fore, allowing the unmet 
medical need and the properties required of the clinical drug 
and its usage to be clearly defined. Using this information, 
the criteria for transition from each stage of the drug discov-
ery process can be clearly defined, even back to making as-
sessments on whether a target could eventually deliver can-
didates which could satisfy the TPP. 
  It is hoped that this review will encourage scientists to 
use TPPs to help assess potential targets, and their progress 
toward the ultimate goal of discovering therapies to alleviate 
the suffering of many of the most under-privileged people in 
the world. In addition we would urge those studying poten-
tial novel targets to generate the appropriate information as a 
matter of course to enable the targets to be assessed for suit-
ability for drug discovery projects. In doing so, a robust 
pipeline of potential anti-parasitic drug targets can be built 
for the future. 
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